• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

11.10 -0.17 (-1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 869,928
Open 11.30
Bid (Size) 11.11 (22)
Ask (Size) 11.20 (1)
Prev. Close 11.27
Today's Range 11.09 - 11.33
52wk Range 6.550 - 13.54
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery
September 29, 2025
Via Stocktwits
Aurinia Responds to Now Retracted LinkedIn Post
September 29, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
+26.6%
+26.6%
1 Month
-13.3%
-13.3%
3 Month
+22.8%
+22.8%
6 Month
+43.6%
+43.6%
1 Year
+55.9%
+55.9%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
September 29, 2025
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen
September 26, 2025
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
September 10, 2025
Via Investor's Business Daily
Topics ETFs
Earnings Scheduled For July 31, 2025
July 31, 2025
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum
September 05, 2025
Via Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
August 26, 2025
Via Investor's Business Daily
Topics ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria
August 15, 2025
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
August 04, 2025
Via Investor's Business Daily
Aurinia (AUPH) Q2 Revenue Jumps 22%
July 31, 2025
Via The Motley Fool
Topics Intellectual Property
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
July 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
July 24, 2025
Via Chartmill
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
July 22, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
July 01, 2025
Via Chartmill
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results
June 30, 2025
Via Stocktwits
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
June 10, 2025
Via Chartmill
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
May 23, 2025
Via Benzinga
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
June 29, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
May 22, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
May 19, 2025
Via Chartmill
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
May 12, 2025
Via Benzinga
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens
May 12, 2025
Via Stocktwits
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
May 12, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 11.10
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 10/13/25 04:00 PM ET
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 1.43B
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 1B shares outstanding.
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap